公开(公告)号：US20200262928A1

公开(公告)日：2020-08-20

申请号：US16651908

申请日：2018-10-22

Applicant: GREEN CROSS CORPORATION ,  MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Ki Su KIM ,  Jung Hong JEONG ,  Dong Sik KIM ,  Yang Mi LIM ,  Yong Yea PARK ,  Hyung Kwon LIM ,  Jong Wha WON

IPC: C07K16/30 ,  C12N15/85

Abstract: The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.

公开(公告)号：US20220162310A1

公开(公告)日：2022-05-26

申请号：US17602511

申请日：2020-05-22

Applicant: GREEN CROSS CORPORATION ,  MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Hye-Young PARK ,  Eun Jung SONG ,  Eun Hee LEE ,  Hye In YUM ,  Hye Mi NAM ,  Mun Kyung KIM ,  Jee Won LEE ,  Joong Hyuk SHEEN ,  Min Kyu HUR ,  So Jung LIM ,  Ok Jae LIM ,  Yang Mi LIM ,  Jong Hwa WON

IPC: C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395

Abstract: The present invention relates to: an antibody to T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains (TIGIT), or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector carrying the nucleic acid; a cell transformed with the vector; a method for producing the antibody or the antigen-binding fragment thereof; and a composition and a composition for combined administration, which comprise same and are for preventing or treating cancer.